The effect of vitamin D and zoledronic acid in bone marrow adiposity in kidney transplant patients: A post hoc analysis

Imagem de Miniatura
Arquivos
art_HERNANDEZ_The_effect_of_vitamin_D_and_zoledronic_acid_2018.PDF (13.56 MB)
Citações na Scopus
3
Tipo de produção
article
Data de publicação
2018
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
PUBLIC LIBRARY SCIENCE
Autores
HERNANDEZ, Mariel J.
BARRETO, Fellype C.
Citação
PLOS ONE, v.13, n.5, article ID e0197994, 17p, 2018
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Purpose Osteoblasts and adipocytes are derived from mesenchymal stem cells. An imbalance in the differentiation of these lineages could affect the preservation of bone integrity. Several studies have suggested the importance of this imbalance in the pathogenesis of osteoporosis after kidney transplant (KT), but the role of bone marrow adiposity in this process is not well known, and if the treatment with the anti-absorptive (zoledronic acid-ZA) drugs could attenuate bone loss. Thus, our objective was compare bone marrow adiposity, osteoblasts and osteocytes before and after KT, verify an association between bone remodeling process (Turnover, Volume, and Mineralization-TMV classification), the osteocyte sclerostin expression to evaluate if there is a role of Wnt pathway, as well as the effect of ZA on these cells. Methods We studied 29 new living-adonor KT patients. One group received ZA at the time of KT plus cholecalciferol for twelve months, and the other group received only cholecalciferol. Bone biopsies were performed at baseline and after 12 months of treatment. Histomorphometric evaluation was performed in bone and bone marrow adipocytes. Sclerostin (Scl) expression in osteocytes was evaluated by immunohistochemistry. Results Some bone marrow adiposity parameters were increased before KT. After KT, some of them remained increased and they worsened with the use of ZA. In the baseline, lower bone Volume and Turnover, were associated with increased bone marrow adiposity parameters (some of them). After KT, both groups showed the same associations. Osteocyte Scl expression after KT decreased with the use of ZA. We observed also an inverse association between bone adiposity parameters and lower osteocyte sclerostin expression 12 months after KT. Conclusion In conclusion, the present study suggests that KT fails to normalize bone marrow adiposity, and it even gets worse with the use of ZA. Moreover, bone marrow adiposity is inversely associated with bone Volume and Turnover, which seems to be accentuated by the antiresorptive therapy.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/27107
Referências
  1. Berendsen AD, 2014, CELL MOL LIFE SCI, V71, P493, DOI 10.1007/s00018-013-1440-z
  2. Boivin GY, 2000, BONE, V27, P687, DOI 10.1016/S8756-3282(00)00376-8
  3. Bonani M, 2014, KIDNEY BLOOD PRESS R, V39, P230, DOI 10.1159/000355781
  4. Carvalho C, 2016, NEPHROLOGY, V21, P55, DOI 10.1111/nep.12570
  5. Charbord P, 2010, HUM GENE THER, V21, P1045, DOI 10.1089/hum.2010.115
  6. Chavassieux PM, 2000, J BONE MINER RES, V15, P754, DOI 10.1359/jbmr.2000.15.4.754
  7. Coco M, 2012, J AM SOC NEPHROL, V23, P1426, DOI 10.1681/ASN.2011060623
  8. Cohen A, 2015, OSTEOPOROSIS INT, V26, P2471, DOI 10.1007/s00198-015-3161-7
  9. Cohen A, 2012, J CLIN ENDOCR METAB, V97, P2782, DOI 10.1210/jc.2012-1477
  10. Contador D, 2015, EXP BIOL MED, V240, P1235, DOI 10.1177/1535370214566565
  11. Cunningham J, 2007, J AM SOC NEPHROL, V18, P223, DOI 10.1681/ASN.2006050427
  12. de Oliveira RA, 2015, KIDNEY INT, V87, P1039, DOI 10.1038/ki.2014.372
  13. Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
  14. Dos Reis LM, 2007, J BONE MINER METAB, V25, P400, DOI 10.1007/s00774-007-0778-4
  15. Duque G, 2011, OSTEOPOROSIS INT, V22, P1547, DOI 10.1007/s00198-010-1353-8
  16. Duque G, 2007, J BONE MINER RES, V22, P1603, DOI 10.1359/JBMR.070701
  17. Duque G, 2013, J BONE MINER RES, V28, P639, DOI 10.1002/jbmr.1782
  18. Fairfield Heather, 2017, Curr Mol Biol Rep, V3, P114, DOI 10.1007/s40610-017-0057-7
  19. Giovanini AF, 2018, ENDOCRINE, V59, P685, DOI 10.1007/s12020-017-1490-3
  20. Gomes SA, 2008, J BONE MINER METAB, V26, P110, DOI 10.1007/s00774-007-0788-2
  21. Graciolli FG, 2017, KIDNEY INT, V91, P1436, DOI 10.1016/j.kint.2016.12.029
  22. Hida Y, 1998, LIFE SCI, V62, pPL205, DOI 10.1016/S0024-3205(98)00059-9
  23. Iyer SP, 2014, J AM SOC NEPHROL, V25, P1331, DOI 10.1681/ASN.2013080851
  24. Justesen J, 2001, BIOGERONTOLOGY, V2, P165, DOI 10.1023/A:1011513223894
  25. Keller H, 2005, BONE, V37, P148, DOI 10.1016/j.bone.2005.03.018
  26. Li GW, 2014, ENDOCRINOLOGY, V155, P4731, DOI 10.1210/en.2014-1359
  27. Li GW, 2013, BONE, V52, P668, DOI 10.1016/j.bone.2012.11.002
  28. Li J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.348
  29. Marques IDB, 2017, OSTEOPOROSIS INT, V28, P1675, DOI 10.1007/s00198-017-3956-9
  30. MELSEN F, 1980, ACTA PATH MICRO IM A, V88, P83
  31. MELSEN F, 1978, CALC TISS RES, V26, P99, DOI 10.1007/BF02013242
  32. Menagh PJ, 2010, J BONE MINER RES, V25, P757, DOI 10.1359/jbmr.091015
  33. Moe S, 2006, KIDNEY INT, V69, P1945, DOI 10.1038/sj.ki.5000414
  34. Molnar MZ, 2014, TRANSPLANT REV-ORLAN, V28, P56, DOI 10.1016/j.trre.2013.12.003
  35. Moorthi RN, 2015, OSTEOPOROSIS INT, V26, P1801, DOI 10.1007/s00198-015-3064-7
  36. Moyses RMA, 2015, INT UROL NEPHROL, V47, P847, DOI 10.1007/s11255-015-0971-7
  37. Neves CL, 2013, TRANSPLANTATION, V96, P290, DOI 10.1097/TP.0b013e3182985468
  38. Ohnaka K, 2005, BIOCHEM BIOPH RES CO, V329, P177, DOI 10.1016/j.bbrc.2005.01.117
  39. Parajuli S, 2016, ADV CHRONIC KIDNEY D, V23, P287, DOI 10.1053/j.ackd.2016.09.006
  40. Pereira RC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138156
  41. Recker RR, 2013, PRIMER METABOLIC BON, P307
  42. Rojas E, 2003, KIDNEY INT, V63, P1915, DOI 10.1046/j.1523-1755.2003.00938.x
  43. Ukita M, 2016, J CELL BIOCHEM, V117, P1419, DOI 10.1002/jcb.25432
  44. Wang FS, 2008, ENDOCRINOLOGY, V149, P1793, DOI 10.1210/en.2007-0910
  45. Watanabe R, 2010, CLIN J AM SOC NEPHRO, V5, P189, DOI 10.2215/CJN.06240909
  46. Wood RJ, 2008, NUTR REV, V66, P40, DOI 10.1111/j.1753-4887.2007.00004.x
  47. Yamamoto S, 2013, J BONE MINER METAB, V31, P116, DOI 10.1007/s00774-012-0391-z

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/16
Artigos e Materiais de Revistas Científicas - ODS/03